Complete Guide to Tacro2 Pharmacokinetics
Overview
Tacro2 is a Calcineurin Inhibitor used in the Transplant / Immunosuppression therapeutic area. It is indicated for Allogeneic hematopoietic cell transplantation (allo-HCT). Interactive two-compartment population PK simulator for oral tacrolimus in adult allogeneic hematopoietic cell transplant (allo-HCT) recipients. Includes CYP3A5 metabolizer phenotype and conditioning regimen intensity covariates. Based on Dunlap et al. (2025) Clin Pharmacokinet.
Mechanism of Action
Tacro2 exerts its pharmacological effect by targeting Calcineurin. As a Calcineurin Inhibitor, it modulates this target to achieve therapeutic efficacy in Allogeneic hematopoietic cell transplantation (allo-HCT). Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK (2-compartment) models for Tacro2:
| Parameter | Value |
|---|---|
| Q | 43 L/h |
| Ka | 0.50 h⁻¹ |
| V1 | 150 L |
| V2 | 1153 L |
| CL F | 23 L/h |
| covariates | CYP3A5 phenotype (PM vs IM/NM), conditioning regimen (MAC vs RIC), body weight |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Tacro2 is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Transplant / Immunosuppression therapeutic area, for the treatment of Allogeneic hematopoietic cell transplantation (allo-HCT), understanding the pharmacokinetics of Tacro2 is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Tacro2 pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Tacro2 PK Simulator
Explore Tacro2 pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Tacro2?
The elimination half-life of Tacro2 depends on patient-specific factors. Use our interactive Tacro2 PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Tacro2 administered?
Tacro2 is administered via the Oral route. It is indicated for Allogeneic hematopoietic cell transplantation (allo-HCT). As a Calcineurin Inhibitor, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Tacro2?
Key pharmacokinetic parameters for Tacro2 include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Tacro2 dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Tacro2 PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.